Hot issues after the release of the guideline for HER2 testing in breast cancer (2024 version)

VernacularTitle:《乳腺癌HER2检测指南（2024版）》发布后的热点问题
Author: Yueping LIU ¹ ; Wentao YANG
Author Information

1. 河北医科大学第四医院　河北省肿瘤医院病理科，石家庄　050011
Publication Type:Journal Article
Keywords: Breast neoplasms; Immunohistochemistry; Hot issues
From: Chinese Journal of Pathology 2025;54(12):1256-1261
CountryChina
Language:Chinese
Abstract: After the release of the guideline for HER2 testing in breast cancer (2024 version), in order to improve the implementation of the guidelines, the Chinese Breast Pathology Group conducted a nationwide survey, gathering feedback from pathologists across China. Based on this, we analyzed and summarized seven key issues commonly encountered in pathological practice. These issues include the heterogeneity of HER2 protein and gene expression, reporting of HER2-ultralow, testing and interpretation issues of HER2 low-level expression, the establishment of external controls for HER2 testing, the interpretation standards for rare staining patterns, and the role of new technologies in HER2-low expression testing. These findings reflect the effectiveness and challenges in the implementation of the guidelines and provide valuable insights for the further optimization of the HER2 testing guidelines in the future.